Dr. Praveen Arany is a trained dentist, oral pathologist, and biomedical engineer. He served as an assistant clinical investigator at NIDCR/NIH, Bethesda, and is currently an associate professor with tenure at the University at Buffalo, New York. He has six patents, over 150 scientific publications with over 12,000 citations, and an h-index of 43. His research has been featured in many mainstream media highlights in over 70 countries. He has also received numerous awards recognizing his research contributions, such as the Excellence in Research award from the World Association for Photobiomodulation Therapy (WALT), the Young Investigator award from the National Cancer Institute/NIH, the Young Investigator Award from the Wound Healing Society, the Horace Furumoto Young Investigator award from the American Society for Laser Medicine and Surgery, and the Theodore Maiman Award from the Academy of Laser Dentistry. He is the chair of the photobiomodulation (PBM) group in Optica and the former president of WALT, NAALT (North American Association for Photobiomodulation Therapy), and the Lasers & Bio-photonics Group of the International Association of Dental Research.
Dr. Arany has been a key figure in organizing the field of PBM. As an intramural investigator at NIDCR/NIH and in a leadership position at WALT and NAALT, he was instrumental in the adoption of the nomenclature for PBM as an MeSH term for PubMed. Among his other achievements are the demonstration of a novel PBM molecular mechanism involving latent TGF-beta 1 activation, and outlining clinical biomarkers, molecular biomarkers, treatment delivery, and dosimetry. Most recently, he advocated for procedural (insurance) codes to enable safe and effective PBM clinical protocols. This has resulted in clinical practice guidelines recommendations for treating several human diseases and promoting wellness, especially in supportive cancer care.
In India, oral cancer affects over a million people annually. Dr. Arany’s Fulbright-Nehru project is introducing the non-invasive, low-dose, and light PBM therapy for oral cancer patients in India, which has been proven to significantly improve both quality of life and quality of care.